Internal medicine

Biliary tract

Vemurafenib

Dabrafenib

Open label

Biology

Gastroenterology

Cancer

Oncology

Kinase

Trametinib

Biliary tract cancer

Gemcitabine

MAPK/ERK pathway

Metastatic melanoma

Clinical trial

Genetics

Medicine

The Lancet Oncology

Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine testing for BRAFV600E mutations should be considered in patients with biliary tract cancer.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial